REFERENCES
- Düsterberg B, Ellman H, Müller U, et al. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose mnophasic oral contra- ceptive containing gestodene. Gynecol Endocrinol 1996; 10:33–9
- Nevinny-Stickel J. German trial of an oral contracep- tive containing 0.150 mg desogestrel plus 0.020 mg ethinylestradiol. Acta Obstet Gynecol Scand 1988; 44 (Suppl): 19–21
- Newton JR, d’Arcangues C, Hall PE. A review of ‘once a month’ combined injectable contraceptives. Obstet Gynecol 1994;14:1–34
- Teichmann A, Corbin A. Clinical experience with a monophasic oral contraceptive containing 150 mg levonorgestrel and 30 mg ethinylestradiol: efficacy, tolerance and metabolic interactions. Stuttgart/New York: Thieme, 1998:81–91
- Spona J, Feichtinger W, Kindermann Ch, Wünsch C, Brill K. Inhibition of ovulation by an oral contraceptive containing 100 mg levonorgestrel in combination with 20 mg ethinylestradiol. Contraception 1996;54:299–304
- Bannemerschult R, Hanker JP, Wünsch C, et al. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 mg ethinylestradiol and 100 mg levonorgestrel over six treatment cycles. Contraception 1997;56:285–90
- Hite RC, Bannemerschult R, Fox-Kuchenbecker P, Turck R, Brill K. Large observational trial of a new low-dose oral contraceptive containing 20 mg ethinylestradiol and 100 mg levonorgestrel (MiranovaÒ) in Germany. Eur J Contracept Reprod Health Care 1999;4:7–13
- Goebelsmann U, Hoffman D, Chiang S, Woutersz T. The relative bioavailability of levonorgestrel and ethinylestradiol administered as a low-dose combina- tion oral contraceptive. Contraception 1986;34:341–51
- Back DJ, Killick SR, Stevenson PJ, Shenoy N, Elstein M, Cohen M. The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form. Contraception 1987;36:321–6
- Hümpel M, Wendt H, Pommerenke G, Weiß C, Speck U. Investigations of pharmacokinetics of levonorgestrel to specific consideration of a possible first-pass effect in women. Contraception 1978;17:207–20
- Fotherby K. Levonorgestrel clinical pharmacokinetics. Clin Pharmacokinet 1995;28:203–15
- Kuhnz W, Al-Yacoub G, Fuhrmeister A. Pharmaco- kinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. Contraception 1992; 46:455–69
- Kuhnz W, Staks T, Jütting G. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonor- gestrel and influence on free and total testosterone levels in serum. Contraception 1994;50:563–79
- Kuhnz W, Schütt B, Woloszczak R. Influence of changes in the concentration of sex hormone-binding globulin in human serum on the protein binding of the contraceptive steroids levonorgestrel, 3-keto- desogestrel and gestodene. J Steroid Biochem Mol Biol 1994;48:573–80
- Kuhnz W, Louton T, Back DJ, Michaelis K. Radio- immunological analysis of ethinylestradiol in human serum. Drug Res 1993;43:16–21
- Hammond GL, Lähteenmäki PL, Lähteenmäki P, Luukkainen T. Distribution and percentages of non- protein bound contraceptive steroids in human serum. J Steroid Biochem 1982;17:175–80
- Back DJ, Bates M, Breckenridge AM, et al. The pharmacokinetics of levonorgestrel and ethinylestradiol in women – studies with ovran and ovranette. Contra- ception 1981;23:229–39
- Fotherby K. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception 1996;54:59–69